Bristol-myers Squibb Stock News

Equities research analysts forecast that Bristol-Myers Squibb (NYSE:BMY) will post sales of $12.00 billion for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Bristol-Myers Squibbs earnings. The lowest sales estimate is $11.96 billion and the highest is $12.04 billion. Bristol-Myers Squibb posted sales of $11.07 billion during the same []

(PR-inside.com) NEW ORLEANS, LA / ACCESSWIRE / December 4, 2021 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until December 6, 2021 to file lead plaintiff applications in securities class action lawsuits against Bristol-Myers Squibb Company ("BMS" or "the Company") (NYSE:BMY), if they received Contingent Value Rights ("CVRs") in exchange for their shares of Celgene Corporation pursuant to BMS'' acquisition of Celgene on November 20, 2019. These actions are pending in the United States District Court for the Southern District of New York. What You ..

Zhang Financial LLC grew its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 44.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,113 shares of the biopharmaceutical companys stock after buying an additional 1,575 shares during the quarter. Zhang Financial LLCs []

Kestra Advisory Services LLC grew its position in Bristol-Myers Squibb (NYSE:BMY) by 24.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 261,773 shares of the biopharmaceutical companys stock after purchasing an additional 50,685 shares during the period. Kestra Advisory Services LLCs holdings in Bristol-Myers Squibb []

It''s still early, but so far so good.

Annaly Capital Management, Inc. (NLY) with the stream of -0.49% also noticed, India Bristol-Myers Squibb Company (BMY) encountered a rapid change of 1.64% in the last hour of Fridays trading The post Hot Stocks Alert: Annaly Capital Management, Inc. (NYSE:NLY), Bristol-Myers Squibb Company (NYSE:BMY) appeared first on Stocks Equity .

It's still early, but so far so good.

NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until December 6, 2021 to file lead plaintiff applications in securities class action lawsuits against Bristol-Myers Squibb Company (BMS or the Company) (NYSE: BMY), if they received Contingent Value Rights (CVRs) (NYSE: BMY.RT) in exchange for their shares of Celgene Corporation (NASDAQ: CELG) pursuant to BMS ac

Anti-obesity therapies are drugs that help people lose or maintain their weight. These drugs affect one of the body''s most basic functions, weight control, by affecting appetite or calorie absorption. Diet and physical activity remain the main therapeutic strategies for

The FDA has accepted for review Bristol Myers Squibb Co''s (NYSE: BMY ) supplemental application seeking approval for Reblozyl (luspatercept-aamt) in adults with non-transfusion dependent (NTD) beta-thalassemia. The FDA has set a Prescription Drug User … Full story available on Benzinga.com

Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Protagonist to Discontinue Development Of Early-Stage Inflammatory Diseases Drug And Focus On PN-235 Protagonist Therapeutics (NASDAQ: PTGX ) said it has selected PN-235 as the final candidate for all clinical studies in multiple indications based on intervention of the Interleukin-23 pathway, under its collaboration with Johnson & Johnson, Inc.''s (NYSE: JNJ ) Janssen unit. In addition to the previously announced Phase 2 clinical study of PN-235 in psoriasis, new Phase 2 clinical studies of PN-235 in inflammatory bowel diseases are expected to commence in late 2022. Further development of PN-232 will be discontinued in favor of PN-235 based on its superior potency, and overall pharmacokinetic and pharmacodynamic profile, the company added. The stock was down 3.64% to $31.50 in premarket trading. Click here to access Benzinga''s FDA Calendar Bristol-Myers Squibb Says Application For Expanding Label For Reblozyl Accepted For Priority Review Bristol-Myers Squibb Company (NYSE: BMY ) announced that the U.S.

The FDA has accepted for review Bristol Myers Squibb Co's (NYSE: BMY) supplemental application seeking approval for Reblozyl (luspatercept-aamt) in adults with non-transfusion dependent (NTD) beta-

The stock price of Bristol Myers Squibb has seen a decline of 8% over the last month, while it is down 6% over the last week. This can partly be attributed to a larger decline in the broader markets w

You can count on these two to deliver strong numbers next year and beyond.